COST EFFECTIVENESS MODEL OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC) IN FRENCH SETTING

被引：0
|
作者：
de Gennes, Dubois C. [1 ]
Mazaleyrat, B. [2 ]
Alvarez, Sanchez J. [3 ]
Lueza, B. [4 ]
机构：
[1] Amaris, Levallois Perret, France
[2] Roche, Boulogne Billancourt, France
[3] F Hoffman La Roche Ltd, Basel, BS, Switzerland
[4] Amaris Consulting, Stockholm, Sweden
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB49
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [21] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    CANCERS, 2021, 13 (05) : 1 - 13
  • [22] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [23] Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
    Wang, Siying
    Xie, Ouyang
    Wu, Meiyu
    Xiang, Heng
    Tan, Chongqing
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024,
  • [24] Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses
    Mohammadnezhad, Ghader
    Esmaily, Hadi
    Talebi, Maryam
    Jafari, Matin
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (02) : 625 - 637
  • [25] Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tanaka, Takaaki
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Naganuma, Atsushi
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Iijima, Hiroko
    Hiasa, Yoichi
    Kumada, Takashi
    HEPATOLOGY RESEARCH, 2022, 52 (05) : 462 - 470
  • [26] Efficacy of atezolizumab (atezo) plus bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
    He, A. R. R.
    Numata, K.
    Lee, K-H.
    Hsu, C-H.
    Lee, J.
    Morimoto, M.
    Verret, W.
    Hack, S. P.
    Spahn, J.
    Liu, B.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S690 - S690
  • [27] Atezolizumab plus bevacizumab combination therapy compared to sorafenib and atezolizumab monotherapies for treatment of unresectable or metastatic hepatocellular carcinoma
    Ahmed, Faiza
    Guntipalli, Prathima
    Yukselen, Zeynep
    Coronel, Maria-Kassandra
    Zaidi, Madiha
    Onwumeh-Okwundu, Jennifer
    Garimella, Vamsi
    Gudapati, Sravya
    Mezidor, Marc-Darlene
    Andrews, Kim
    Mouchli, Mohamad
    Shahini, Endrit
    Mohan, Karthik
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 69 - 70
  • [28] Evans’ syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma
    Masanori Fukushima
    Kazuaki Tajima
    Ryu Sasaki
    Yasuhiko Nakao
    Kosuke Takahashi
    Eisuke Ozawa
    Satoshi Miuma
    Takeharu Kato
    Hisamitsu Miyaaki
    Kazuhiko Nakao
    Clinical Journal of Gastroenterology, 2023, 16 : 402 - 406
  • [29] Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients
    Kim, Hyeyeong
    Cheon, Jaekyung
    Ha, Yeongjung
    Kim, Han Sang
    Kim, Chang Gon
    Kim, Ilhwan
    Kim, Chan
    Jung, Sang-Hoon
    Chon, Hong Jae
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma
    Fukushima, Masanori
    Tajima, Kazuaki
    Sasaki, Ryu
    Nakao, Yasuhiko
    Takahashi, Kosuke
    Ozawa, Eisuke
    Miuma, Satoshi
    Kato, Takeharu
    Miyaaki, Hisamitsu
    Nakao, Kazuhiko
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (03) : 402 - 406
12345